These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 9795471)

  • 61. Risk factors for reflux esophagitis after eradication of
    Harada A; Kurahara K; Moriyama T; Tanaka T; Nagata Y; Kawasaki K; Yaita H; Maehata Y; Umeno J; Oshiro Y; Fuchigami T; Kitazono T; Esaki M; Matsumoto T
    Scand J Gastroenterol; 2019 Oct; 54(10):1183-1188. PubMed ID: 31577454
    [No Abstract]   [Full Text] [Related]  

  • 62. Factors associated with the development of reflux esophagitis after Helicobacter pylori eradication.
    Tsukada K; Katoh H; Miyazaki T; Fukuchi M; Kuwano H; Kimura H; Fukai Y; Inose T; Motojima T; Toda N; Yamada S
    Dig Dis Sci; 2006 Mar; 51(3):539-42. PubMed ID: 16614964
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Proton pump inhibitors (PPIs) may cause gastric cancer - clinical consequences.
    Waldum HL; Sørdal Ø; Fossmark R
    Scand J Gastroenterol; 2018 Jun; 53(6):639-642. PubMed ID: 29852782
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Elderly women who received Helicobacter pylori-eradicating therapy have reduced risk of low skeletal muscle mass.
    Baeg MK; Choi MG; Ko SH; Lim CH; Kim JS; Cho YK; Park JM; Cho YS; Lee BI; Lee IS
    Clin Interv Aging; 2015; 10():1771-7. PubMed ID: 26586939
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Helicobacter pylori and gastroesophageal reflux disease.
    Metz DC; Kroser JA
    Gastroenterol Clin North Am; 1999 Dec; 28(4):971-85, viii. PubMed ID: 10695012
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effect of Helicobacter pylori infection and its eradication on nutrition.
    Furuta T; Shirai N; Xiao F; Takashima M; Hanai H
    Aliment Pharmacol Ther; 2002 Apr; 16(4):799-806. PubMed ID: 11929399
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Active and inactive gastroesophageal reflux diseases related to Helicobacter pylori therapy.
    Nakajima S; Hattori T
    Helicobacter; 2003 Aug; 8(4):279-93. PubMed ID: 12950600
    [TBL] [Abstract][Full Text] [Related]  

  • 68. H pylori eradication and GERD.
    Fishman M
    Can J Gastroenterol; 2001 Jul; 15(7):427. PubMed ID: 11493942
    [No Abstract]   [Full Text] [Related]  

  • 69. Helicobacter pylori infection has no impact on manometric and pH-metric findings in adolescents and young adults with gastroesophageal reflux and antral gastritis: eradication results to no significant clinical improvement.
    Xinias I; Maris T; Mavroudi A; Panteliadis C; Vandenplas Y
    Pediatr Rep; 2013 Feb; 5(1):e3. PubMed ID: 23667732
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pathological issues of gastric and lower esophageal cancer: helicobacter pylori infection and its eradication.
    Fujimori T; Kawamata H; Ichikawa K; Ono Y; Okura Y; Tomita S; Imura J
    J Gastroenterol; 2002; 37 Suppl 13():28-33. PubMed ID: 12109662
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Helicobacter pylori infection increases risk of incident metabolic syndrome and diabetes: A cohort study.
    Chen YY; Fang WH; Wang CC; Kao TW; Chang YW; Wu CJ; Zhou YC; Sun YS; Chen WL
    PLoS One; 2019; 14(2):e0208913. PubMed ID: 30779804
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Environmental - lifestyle related factors.
    Roman S; Pandolfino JE
    Best Pract Res Clin Gastroenterol; 2010 Dec; 24(6):847-59. PubMed ID: 21126698
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The 1998 national Belgian consensus meeting on HP-related diseases: an extensive summary. The HP Belgian contact group organized in CHU Brugmann, Brussels.
    Deltenre M; Geboes K; Ectors N; Burete A; Debongnie JC; Lamy V; Cadranel S; Colemont L; De Koster E; De Prez C; Deprez P; Dumonceau JM; Glupczunski Y; Mélange M; Peeters M; Ramdani B; Scaillon M
    Acta Gastroenterol Belg; 1998; 61(3):299-302. PubMed ID: 9795458
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.
    Creutzfeldt W
    Drug Saf; 1994 Jan; 10(1):66-82. PubMed ID: 8136088
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The prevalence of Helicobacter pylori infection in benign laryngeal disorders.
    Rubin JS; Benjamin E; Prior A; Lavy J; Ratcliffe P
    J Voice; 2002 Mar; 16(1):87-91. PubMed ID: 12002892
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The role of Helicobacter pylori and CagA in response to treatment in Iranian Gastroesophageal Reflux Diseases patients.
    Khoshbaten M; Baghaei K; Bafandeh Y; Saeidi GR; Gachkar L; Al Dulaimi D; Lamouki RM; Rostami Nejad M; Bonyadi MR
    Gastroenterol Hepatol Bed Bench; 2013; 6(Suppl 1):S93-8. PubMed ID: 24834295
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Impact of gastric Helicobacter pylori infection on nasal mucociliary clearance.
    Şahin E; Katar MK; Haberal Can I
    Eur Arch Otorhinolaryngol; 2020 Oct; 277(10):2761-2765. PubMed ID: 32476044
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Improvement of reflux symptom related quality of life after Helicobacter pylori eradication therapy.
    Hirata K; Suzuki H; Matsuzaki J; Masaoka T; Saito Y; Nishizawa T; Iwasaki E; Fukuhara S; Okada S; Hibi T
    J Clin Biochem Nutr; 2013 Mar; 52(2):172-8. PubMed ID: 23524980
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Gastric carcinoma of the fundic gland type developed 32 years after
    Suto D; Sato K; Yoshida M; Ota H; Otake T; Osawa Y; Nakazato Y; Ohdaira H; Suzuki Y; Kohgo Y
    Ann Med Surg (Lond); 2024 Jul; 86(7):4227-4230. PubMed ID: 38989225
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of
    Shen H; Chen Y; Li X; Yan J; Zhao J; Kong D; Shi Y; Li Z; Wang J; Shao N; Wang Z
    Evid Based Complement Alternat Med; 2022; 2022():8266321. PubMed ID: 35836834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.